Ginkgo Bioworks Holdings (DNA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NYSE
Market Cap: $622.97M
Last updated: Nov 17, 2026 at 11:03 AM ET
Ginkgo Bioworks Holdings (DNA) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Ginkgo Bioworks Holdings reported EPS of -$0.64, below the -$0.58 estimate. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
DNA's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
DNA Earnings Call
The latest DNA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 19 quarters below that had an estimate, DNA beat 7, missed 11 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $27.71M, down 5.7% from $29.38M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.64 | -$0.58 | -$0.58 - -$0.50 | -10.34% | Miss | N/A | 2 | 0 up, 0 down | Nov 5, 2026 | $27.71M |
| Jun 30, 2026 | -$0.86 | -$0.70 | -$0.70 - -$0.70 | -22.86% | Miss | N/A | 1 | 0 up, 0 down | Aug 5, 2026 | $20.16M |
| Mar 31, 2026 | -$1.39 | -$1.34 | -$1.34 - -$1.34 | -3.73% | Miss | N/A | 1 | 0 up, 1 down | May 7, 2026 | $19.47M |
| Dec 31, 2025 | -$1.42 | -$1.80 | N/A | +21.11% | Beat | N/A | 1 | 0 up, 0 down | Feb 26, 2026 | $33.40M |
| Sep 30, 2025 | -$1.45 | -$1.24 | -$1.27 - -$1.21 | -16.94% | Miss | N/A | 3 | 2 up, 1 down | Nov 6, 2025 | $29.38M |
| Jun 30, 2025 | -$1.10 | -$1.44 | N/A | +23.61% | Beat | N/A | N/A | 0 up, 0 down | Aug 7, 2025 | $39.13M |
| Mar 31, 2025 | -$1.68 | -$1.77 | N/A | +5.08% | Beat | N/A | N/A | 0 up, 0 down | May 6, 2025 | $38.23M |
| Dec 31, 2024 | -$2.00 | -$0.06 | N/A | N/A | N/A | N/A | 1 | 0 up, 1 down | Feb 25, 2025 | $43.85M |
| Sep 30, 2024 | -$1.08 | -$3.32 | N/A | +67.47% | Beat | N/A | 3 | 1 up, 0 down | Nov 12, 2024 | $89.05M |
| Jun 30, 2024 | -$4.40 | -$3.12 | -$3.20 - -$2.80 | -41.03% | Miss | N/A | 5 | 0 up, 0 down | Aug 8, 2024 | $56.21M |
| Mar 31, 2024 | -$0.08 | -$0.08 | -$0.10 - -$0.08 | 0.00% | In line | N/A | 6 | 0 up, 0 down | May 9, 2024 | $37.94M |
| Dec 31, 2023 | -$2.94 | -$2.80 | -$5.60 - -$2.40 | -5.00% | Miss | N/A | 6 | 0 up, 0 down | Feb 29, 2024 | $34.76M |
| Sep 30, 2023 | -$3.65 | -$3.20 | -$4.00 - -$2.40 | -14.06% | Miss | N/A | 7 | 0 up, 0 down | Nov 8, 2023 | $55.43M |
| Jun 30, 2023 | -$3.06 | -$3.50 | -$4.40 - -$2.40 | +12.57% | Beat | N/A | 7 | 0 up, 0 down | Aug 9, 2023 | $80.57M |
| Mar 31, 2023 | -$3.89 | -$3.90 | -$4.80 - -$2.40 | +0.26% | Beat | N/A | 6 | 0 up, 0 down | May 10, 2023 | $80.70M |
| Dec 31, 2022 | -$0.09 | -$0.21 | -$0.42 - -$0.05 | +57.14% | Beat | N/A | 7 | 0 up, 0 down | Mar 1, 2023 | $98.28M |
| Sep 30, 2022 | -$16.51 | -$9.68 | -$16.40 - -$2.40 | -70.56% | Miss | N/A | 5 | 0 up, 0 down | Nov 14, 2022 | $66.40M |
| Jun 30, 2022 | -$16.44 | -$5.44 | N/A | -202.21% | Miss | N/A | 3 | 0 up, 0 down | Aug 15, 2022 | $144.62M |
| Mar 31, 2022 | -$14.80 | -$7.40 | N/A | -100.00% | Miss | -49433.3% | 3 | 0 up, 0 down | May 16, 2022 | $168.41M |
| Dec 31, 2021 | -$0.99 | -$0.04 | -$0.06 - -$0.01 | N/A | N/A | N/A | 6 | 0 up, 0 down | Mar 28, 2022 | $148.49M |
| Sep 30, 2021 | -$3.20 | -$1.40 | -$1.60 - -$1.20 | -128.57% | Miss | N/A | 2 | N/A | Nov 15, 2021 | $77.61M |
| Jun 30, 2021 | -$0.50 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 20, 2021 | $43.64M |
| Mar 31, 2021 | $0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 24, 2021 | $44.10M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$5.65, after -$7.56 the year before. It was -$4.66 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$5.65 | N/A |
| Dec 31, 2024 | -$7.56 | N/A |
| Dec 31, 2023 | -$13.54 | N/A |
| Dec 31, 2022 | -$47.84 | N/A |
| Dec 31, 2021 | -$4.66 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,300 words across 3 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,264 | 3 | |
| 2026Q2 | Jun 30, 2026 | 7,115 | 3 | |
| 2026Q1 | Mar 31, 2026 | 4,178 | 4 | |
| 2025Q4 | Dec 31, 2025 | 3,789 | 3 | |
| 2025Q3 | Sep 30, 2025 | 4,080 | 3 | |
| 2025Q2 | Jun 30, 2025 | 6,501 | 3 | |
| 2025Q1 | Mar 31, 2025 | 2,242 | 5 | |
| 2024Q4 | Dec 31, 2024 | 5,247 | 6 |
2026Q3 Earnings Call
Opening remarks
Daniel Marshall Manager of Communications and Ownership I'm joined by Jason Kelly, our Co-Founder and CEO, and Steve Coen, our CFO. Thanks, as always, for joining us. We're looking forward to updating you on our progress. As a reminder, during the presentation today, we will be making forward-looking statements, which involve risks and uncertainties. Please refer to our filings with the SEC to learn more about these risks and uncertainties, including our most recent 10-K. Today, in addition to updating you on the quarter's results, we're going to show how Ginkgo is now two businesses built on one autonomous lab platform at a moment when the U.S. government is starting to treat autonomous labs as national infrastructure. We'll share how our autonomous labs business is growing, including our first autonomous lab sale to a pharma company, Novo, alongside new government wins with ARPA-H and the NSF. We'll also share how our cloud lab business is growing with new pharma logos, including 22 customers this quarter, and with AI data generation for frontier labs. As usual, we'll end with a Q&A session, and I'll take questions from analysts, investors, and the public. You can submit those questions to us in advance via X, #GinkgoResults, or email investors@ginkgobioworks.com. All right. Over to you, Jason.
Jason Kelly Co-Founder and CEO Thanks, Daniel. As I always say, our mission here at Ginkgo is to make biology easier to engineer. Over the last few years, we've been going through a transformation with this focus on autonomous labs, and that was really our goal in 2026. I would say I think that succeeded very well, and this quarter is really good evidence of that. We've been focusing our efforts on moving more and more of our internal lab work onto autonomous labs. That continues, along with improving the product. But there was a real breakthrough in the last quarter in terms of external customers adopting our systems. And so we'll be happy to talk about some of the new customers we have for autonomous labs, both in universities and the biopharma sector, and we've been expanding the services that we're offering on top of our big system in Boston here in Nebula. So, really happy about this. I think we made the right choice in betting on this technology. So you're going to hear more from me on that in the strategic section. Also, our financials have been going in the right direction. We made a big push to cut back on spending while still making major investments in research and development around autonomous labs, AI, and robotics in the laboratory, and that has also paid off.
Frequently Asked Questions About DNA
Did DNA beat earnings estimates last quarter?
No. Ginkgo Bioworks Holdings reported EPS of -$0.64 for the quarter ended Sep 30, 2026, below the -$0.58 estimate by 10.34%.
What EPS do analysts expect from DNA next quarter?
The consensus EPS estimate for Ginkgo Bioworks Holdings for the quarter ending Dec 31, 2026 is -$1.27 from 2 analysts.
How often does DNA beat earnings estimates?
Ginkgo Bioworks Holdings beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of +7.93%.
DNA pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts